Pipeline· May 31, 2026 · 10 min readOlezarsen (Tryngolza) severe hypertriglyceridemia sNDA preview: first therapy to reduce pancreatitis risk in 3 million US adultsIonis Pharmaceuticals awaits a June 30, 2026 FDA decision on olezarsen (Tryngolza) for severe hypertriglyceridemia. Already approved...By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence
Pipeline· May 31, 2026 · 10 min readVeligrotug vs Tepezza: the second TED therapy approaches FDA approval with a shorter infusion schedule and broader indicationViridian Therapeutics' veligrotug has a PDUFA date of June 30, 2026 for thyroid eye disease. If approved, it would be the second...By Ran Chen#PDUFA Date#FDA Approval#Ophthalmology
